Brain metastases: fractionated whole-brain radiotherapy

Handb Clin Neurol. 2018:149:123-127. doi: 10.1016/B978-0-12-811161-1.00009-8.

Abstract

Brain metastases are the most common malignant adult intracranial tumors, occurring in approximately 10-30% of cancer patients, and generally lead to a poor prognosis. The incidence has been steadily rising, likely due to longer survival from newer systemic therapies and increased utilization of magnetic resonance imaging. Historically, whole-brain radiotherapy has been a standard of care for the management of patients with brain metastases. However, better understanding of both the acute and long-term toxicities associated with whole-brain radiotherapy has led to a more selective use of whole-brain radiotherapy. Herein we discuss the background and prognostication of brain metastases as well as the role of palliative whole-brain radiotherapy, as monotherapy and adjuvant use after resection or stereotactic radiosurgery. We also review refined whole-brain radiation techniques, potential neuroprotective drugs, and ongoing trials.

Keywords: brain metastases; fractionated radiotherapy; hippocampal avoidance; whole-brain radiotherapy.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / radiotherapy*
  • Brain Neoplasms / secondary
  • Brain Neoplasms / surgery
  • Cranial Irradiation / methods*
  • Humans
  • Neoplasms / pathology
  • Radiosurgery / methods